RegulatoryBusiness Standard
USFDA issues 7 observations to NATCO Pharma
GreyOak summary
NATCO Pharma Limited received seven observations from the USFDA following an inspection of its Hyderabad manufacturing facility conducted between November 12 and 20. The regulator cited conditions that may constitute violations of laws in Form 483. The company stated these observations are procedural and expressed confidence in addressing them within the stipulated timelines.
What it affects
- Natco PharmaNATCOPHARMNegative -33
Received 7 USFDA observations on its plant.Rolling sentiment Negative -34
Source
Reported by Business Standard
- Business Today
- BusinessLine
- Economic Times
- Economic Times
- Economic Times
- CNBC-TV18
- Business Standard
More Natco Pharma news
- USFDA issues 7 observations to NATCO PharmaBusinessLine · Regulatory ·
- Natco Pharma receives EIR from US FDA for Visakhapatnam plantCNBC-TV18 · Company update ·
- Buy Natco Pharma: target of Rs 1065: ICICI SecuritiesMoneycontrol · Company update ·
- Natco Pharma shares rally 9% despite weak Q2 resultsNDTV Profit · Results ·